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EDITORIAL
Diagnostic predictive value of ANCA serology
In this issue of Kidney International, Chris Hagen and his
collaborators in the European ANCA (anti-neutrophil cytoplas-
mic autoantibodies) Assay Standardization Project provide ex-
tremely useful information from their evaluation of immunofluo-
rescence assays (IFA) and enzyme immunoassays (EIA) for
ANCA in serum [1]. They conclude that combining IFA testing
for C-ANCA and P-ANCA with EIA testing for anti-proteinase 3
antibodies (PR3-ANCA) and anti-myeloperoxidase antibodies
(MPO-ANCA) is more accurate than either IFA or EIA alone for
detecting ANCA, and thus is a more useful adjunct for diagnosing
ANCA associated diseases.
The major ANCA associated diseases of importance to neph-
rologists are microscopic polyangiitis, Wegener’s granulomatosis,
and necrotizing “idiopathic” crescentic glomerulonephritis with-
out systemic vasculitis [1, 2]. The specificity of ANCA for PR3 or
MPO does not effectively differentiate between these clinicopath-
ologic categories of disease. For example, in the study by Hagen
et al, PR3-ANCA positivity was detected by EIA in 66% of
Wegener’s granulomatosis patients, 26% of microscopic polyan-
giitis patients, and 50% of patients with idiopathic crescentic
glomerulonephritis alone, whereas MPO-ANCA positivity was
detected in 24% of Wegener’s granulomatosis patients, 58% of
patients with microscopic polyangiitis, and 64% of patients with
idiopathic crescentic glomerulonephritis alone [1]. However, pos-
itivity for either C-ANCA plus PR3-ANCA, or P-ANCA plus
MPO-ANCA is a useful serologic marker for this group of
ANCA-associated diseases.
Renal involvement in each of these diseases is characterized by
aggressive necrotizing glomerulonephritis, usually with crescents
and an absence or paucity of glomerular localization of immuno-
globulins (that is, pauci-immune crescentic glomerulonephritis).
Therefore, when nephrologists request an ANCA assay, they
usually are considering a diagnosis of pauci-immune crescentic
glomerulonephritis, either with or without associated systemic
small vessel vasculitis.
The European collaborative study determined that, in their
prospectively enrolled patients, 111 of 153 patients with pauci-
immune crescentic glomerulonephritis (that is, patients with
either microscopic polyangiitis, Wegener’s granulomatosis, or
pauci-immune crescentic glomerulonephritis alone) were positive
by combined IFA and EIA, and 181 of 184 disease control
patients with other types of inflammatory systemic or renal
diseases were not positive in both assays [1]. Thus, the sensitivity
of combined IFA and EIA testing was 72.5% (111 of 153) and the
specificity was 98.4% (181 of 184) in the assay systems that they
used.
What does this mean with respect to diagnostic utility? How
confident can a nephrologist be that an ANCA-positive patient
has pauci-immune crescentic glomerulonephritis, and, just as
importantly, that an ANCA-negative patient does not have pauci-
immune crescentic glomerulonephritis? In other words, what are
the positive predictive value (PPV) and negative prediction value
(NPV) of the ANCA results? The PPV is the percentage of
positive patients who have the disease [true positives 4 (true
positives 1 false positives) 3 100] and the NPV is the percentage
of negative patients who do not have the disease [true negatives 4
(true negatives 1 false negatives) 3 100] [3].
The predictive value of any laboratory test is determined not
only by the sensitivity and specificity of the test, but also by the
prevalence of the disease in patients who have signs and symp-
toms similar to those in the patient who is being tested. It is
extremely important to understand that the predicted prevalence
of an uncommon disease varies tremendously among patients with
different clinical manifestations, and, therefore, the predictive
value of a laboratory test for that disease also varies tremendously
among patients with different clinical manifestations.
To determine the predictive value of ANCA testing, we com-
bined the sensitivity and specificity data from the study by Hagen
et al with prevalence data from a cohort of 4,185 consecutive
patients who had undergone renal biopsy examination in the
University of North Carolina Nephropathology Laboratory and
had adequate tissue for evaluation by light, immunofluorescence,
and electron microscopy, as well as urinalysis and serum creati-
nine data. The pathologic and clinical data had been prospectively
entered into the U.N.C. Nephropathology Laboratory Database.
This cohort of patients was subdivided based on clinical presen-
tations and age. The prevalence of pauci-immune crescentic
glomerulonephritis was determined for each subset (Tables 1 to
3). For the purposes of this evaluation, pauci-immune crescentic
glomerulonephritis was defined as glomerulonephritis with cres-
cents by light microscopy, less than 21 on a scale of 0 to 41
staining for any immunoglobulins, and no electron dense deposits
by electron microscopy. The prevalence data for pauci-immune
crescentic glomerulonephritis (first column of Tables 1 through 3)
were then used to calculate PPV and NPV (second and third
columns of Tables 1 through 3) of ANCA results in patients with
different clinical presentations based on the sensitivity (72.5%)
and specificity (98.4%) data from the European collaborative
project [1]. All but one of the clinical categories were based on the
urinalysis and serum creatinine data at the time of biopsy. The
other category was defined on the basis of crescents in . 50% of
glomeruli in a renal biopsy specimen, which was used as a
pathologic surrogate marker for a clinical presentation of rapidly
progressive glomerulonephritis.
Tables 1 to 3 show that the prevalence of pauci-immune
crescentic glomerulonephritis varies substantially with the age and
clinical presentations of patients. Pauci-immune crescentic glo-
merulonephritis is most frequent in patients with evidence for
severe glomerular disease and is least frequent in patients with
hematuria but no significant renal insufficiency. Therefore, the
PPV of a positive ANCA result is much higher in a patient with© 1998 by the International Society of Nephrology
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severe glomerular disease and than in a patient with minor renal
dysfunction. If we consider all adult patients who undergo renal
biopsy and have hematuria and proteinuria at the time of biopsy,
a positive ANCA result has a PPV of 92% in a patient with a
serum creatinine . 3 mg/dl, but this same serologic result in an
adult patient with a serum creatinine , 1.5 mg/dl has a PPV of
only 47% (Table 1). This latter value indicates that more than half
of positive ANCA results are in patients who do not have
pauci-immune crescentic glomerulonephritis, that is, are false
positive results. Thus, the PPV of an ANCA test, and any other
serologic test for that matter, is better in patients whose clinical
signs and symptoms of disease indicate a high pretest likelihood of
the disease for which a positive test result is a marker.
However, it is very important to realize that even in circum-
stances in which the PPV is relatively low, a positive result may
increase the likelihood of a disease to a level that will warrant
additional evaluations to confirm or rule out the disease in
question. For example, in an adult with hematuria, proteinuria
and a serum creatinine of 1.5 to 3 mg/dl, the pretest likelihood of
pauci-immune crescentic glomerulonephritis is only 7%, whereas
the likelihood after a positive ANCA test increases to 77%. This
increase raises the suspicion of pauci-immune crescentic glomer-
ulonephritis to a level that warrants an expeditious renal biopsy to
determine a definitive diagnosis. On the other hand, if this patient
has a negative ANCA test, the likelihood of pauci-immune
crescentic glomerulonephritis falls from 7% to 2% (that is,
100-NPV), which further allays concern for this aggressive form
of glomerulonephritis. A positive ANCA result always in-
creases the post-test likelihood of pauci-immune crescentic
glomerulonephritis and a negative ANCA result always reduces
the likelihood.
The NPV of an ANCA assay provides additional confidence in
ruling out the possibility of pauci-immune crescentic glomerulo-
nephritis, which is an aggressive disease for which there is an
effective treatment and thus should not be overlooked. However,
it is important to realize that a negative ANCA result never
completely rules out the possibility of pauci-immune crescentic
glomerulonephritis, either as a renal-limited disease or as a
component of Wegener’s granulomatosis or microscopic polyan-
giitis. This is particularly true in patients with strong clinical
evidence for this category of disease, such as patients with rapidly
progressive glomerulonephritis or manifestations of systemic
small vessel vasculitis. The NPV of a test is inversely proportional
to the pretest likelihood of the disease and thus is lowest in
patients with strong clinical evidence for the disease. This is in
contrast to the PPV, which is directly proportional to the pretest
likelihood and thus is highest in patients with strong clinical
evidence for the disease. These relationships can be clearly seen in
the final two columns of Tables 1 through 3. Based on these
relationships, ANCA testing in patients with strong clinical evi-
dence for pauci-immune crescentic glomerulonephritis is most
useful for substantiating the diagnosis of pauci-immune crescentic
glomerulonephritis, whereas ANCA testing in patients with weak
clinical evidence for pauci-immune crescentic glomerulonephritis
is most useful for ruling out the diagnosis of pauci-immune
crescentic glomerulonephritis.
In summary, the data provided by Hagen et al further elucidate
the analytical characteristics of ANCA testing and demonstrate
good sensitivity and specificity for pauci-immune crescentic glo-
merulonephritis, which occurs as a renal-limited disease or as a
component of a systemic small vessel vasculitis, such as Wegener’s
Table 1. Estimated positive and negative predictive values of ANCA
results for pauci-immune crescentic glomerulonephritis (PI-CGN) in
adults (.18 years old) with different clinical presentations using an
assay approach that has a 72.5% sensitivity and a 98.4% specificity
Clinical presentation
of patient
Prevalence of
PI-CGN
PPV for
PI-CGN
NPV for
PI-CGN
Rapidly progressive
glomerulonephritisa
47% (106/224) 98% 80%
Hematuria, proteinuria,
and creatinine
. 3 mg/dl
21% (181/862) 92% 93%
Hematuria, proteinuria,
and creatinine 1.5–3
mg/dl
7% (51/685) 77% 98%
Hematuria, proteinuria,
and creatinine
, 1.5 mg/dl
2% (13/768) 47% 99%
a This clinical presentation is presumed from a renal biopsy showing
. 50% of glomeruli with crescents
Table 2. Estimated positive and negative predictive values of ANCA
results for pauci-immune crescentic glomerulonephritis (PI-CGN) in
older adults (.50 years old) with different clinical presentations using
an assay approach that has a 72.5% sensitivity and a 98.4% specificity
Clinical presentation of
patient
Prevalence of
PI-CGN
PPV for
PI-CGN
NPV for
PI-CGN
Rapidly progressive
glomerulonephritisa
66% (82/124) 99% 65%
Hematuria, proteinuria,
and creatinine
. 3 mg/dl
30% (147/497) 95% 89%
Hematuria, proteinuria,
and creatinine 1.5–3
mg/dl
11% (36/311) 85% 97%
Hematuria, proteinuria,
and creatinine
, 1.5 mg/dl
4% (7/195) 66% 99%
a This clinical presentation is presumed from a renal biopsy showing
. 50% of glomeruli with crescents
Table 3. Estimated positive and negative predictive values of ANCA
results for pauci-immune crescentic glomerulonephritis (PI-CGN) in
children (,18 years old) with different clinical presentations using an
assay approach that has a 72.5% sensitivity and a 98.4% specificity
Clinical presentation of
patient
Prevalence of
PI-CGN
PPV for
PI-CGN
NPV for
PI-CGN
Rapidly progressive
glomerulonephritisa
48% (10/21) 98% 80%
Hematuria, proteinuria,
and creatinine
. 3 mg/dl
16% (6/38) 90% 95%
Hematuria, proteinuria,
and creatinine 1.5–3
mg/dl
15% (6/39) 89% 95%
Hematuria, proteinuria,
and creatinine
, 1.5 mg/dl
1% (1/162) 30% 100%
a This clinical presentation is presumed from a renal biopsy showing
. 50% of glomeruli with crescents
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granulomatosis or microscopic polyangiitis [1]. The diagnostic
significance of a positive or negative ANCA test result is dramat-
ically influenced by the clinical manifestations of disease in the
patient from whom the serum sample was obtained. The clinical
characteristics of a patient with a positive ANCA assay result are
as important as the analytical characteristics of the assay in
drawing conclusions about the diagnostic significance of the
result. Thus, the clinician must take into consideration the signs
and symptoms of disease not only when deciding to order an
ANCA assay but also when interpreting the significance of the
results. As with any tool, the usefulness of ANCA testing is
dictated by the skill of the individual who uses it.
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